Asahi Kasei reports developments across a diversified global business that includes healthcare, materials, electronic components, and hydrogen-related technologies. News commonly covers pharmaceutical pipeline expansion, specialty pharmaceutical acquisitions, antiviral and autoimmune-disease programs, and subsidiary activity involving Veloxis Pharmaceuticals, Asahi Kasei Therapeutics, and Asahi Kasei Pharma.
Company updates also include Asahi Kasei Microdevices' magnetic-sensor and photonic technology work, chlor-alkali electrolysis products such as electrolyzer cells, ion-exchange membranes, and electrodes, and Aqualyzer™ alkaline-water electrolyzer deployments for hydrogen production. Recurring themes include research collaborations, license agreements, clinical and regulatory disclosures, material agreements, capital-structure updates, and operating and financial results.
Asahi Kasei announced the construction of a new lithium-ion battery separator plant in Port Colborne, Ontario, Canada. This facility, named Asahi Kasei Battery Separator Canada, will start commercial production in 2027, creating highly skilled, well-paying jobs in manufacturing and construction. The plant will produce Hipore™ wet-process separators for electric vehicle batteries and energy storage. The initial investment is approximately 180 billion JPY (CAD$ 1.56 billion) for 700 million square meters of annual separator capacity. The project is supported by the Ontario provincial government and will benefit from Canada's Clean Technology Manufacturing Investment Tax Credit.
Asahi Kasei has officially inaugurated its multi-module hydrogen pilot plant in Kawasaki, Japan, aimed at advancing its hydrogen business. The plant, which began operations in March 2024, features four 0.8 MW modules and is a important step toward developing a 100 MW-class alkaline water electrolysis system for green hydrogen production. The pilot plant will help optimize equipment design and control technology by operating under realistic conditions. Asahi Kasei plans to commercialize its alkaline water electrolyzers in 2025, targeting sales of ¥100 billion by 2030. The project is supported by Japan's Green Innovation Fund.
Asahi Kasei Bioprocess introduces the THESYS™ ACS ERGO Synthesis Column at TIDES USA, offering reduced changeover time without compromising safety or product quality. The column aims to enhance efficiency in oligonucleotide synthesis, featuring an operator-friendly design for smooth changeovers between runs. AKB's innovative bolt-free design saves time and labor, improving productivity for manufacturers while prioritizing operator safety and product reliability.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.